Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

ALFACALCIDOL FOR SYSTEM SUITABILITY A CRS (5 MG)

ALFACALCIDOL FOR SYSTEM SUITABILITY A CRS (5 MG)

ND

DISCOVER
VINCAMINE FOR SYSTEM SUITABILITY CRS (10 MG)

VINCAMINE FOR SYSTEM SUITABILITY CRS (10 MG)

ND

DISCOVER
MESTEROLONE  FOR SYSTEM SUITABILITY CRS (15 MG)

MESTEROLONE FOR SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER
CARMUSTINE CRS (60 MG)

CARMUSTINE CRS (60 MG)

ND

DISCOVER
CHLORTALIDONE FOR SYSTEM SUITABILITY CRS (1.017 MG)

CHLORTALIDONE FOR SYSTEM SUITABILITY CRS (1.017 MG)

77-36-1

DISCOVER
HIBIFOLIN CRS (15 MG)

HIBIFOLIN CRS (15 MG)

ND

DISCOVER
SQUALENE CRS (500 MG)

SQUALENE CRS (500 MG)

ND

DISCOVER
TOPIRAMATE IMPURITY E CRS (40MG)

TOPIRAMATE IMPURITY E CRS (40MG)

ND

DISCOVER
TOPIRAMATE IMPURITY A CRS (20MG)

TOPIRAMATE IMPURITY A CRS (20MG)

ND

DISCOVER
TOPIRAMATE CRS (70 MG)

TOPIRAMATE CRS (70 MG)

ND

DISCOVER
PROPRANOLOL  FOR SYSTEM SUITABILITY CRS (15 MG)

PROPRANOLOL FOR SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER
OXYTETRACYCLINE FOR SYSTEM SUITABILITY A CRS (20 MG)

OXYTETRACYCLINE FOR SYSTEM SUITABILITY A CRS (20 MG)

NA

DISCOVER